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ABSTRACT 
The complex interactions between Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) infections may 
be magnified, in the presence of another potentially stressful condition like pregnancy. Though co-infection 
among pregnant women is rare, treatment outcomes may depend on accessibility to comprehensive treatment 
modalities. The objective of this study is to determine treatment outcomes among pregnant HIV and TB co-
infected pregnant women in Lagos, South-western Nigeria. This retrospective, analytical study was carried out 
among ninety four (94) eligible pregnant women co-infected with HIV and TB at selected health-care facilities in 
Lagos state between January, 2008 and December, 2009. A standard checklist for data collection was used and 
analysis was carried out using the EPI info software. Mean age of respondents was 30.8 (±3.9) years. Sixteen 
(17.1%) TB cases were clinically diagnosed for tuberculosis. Among tuberculosis cases identified through 
sputum microscopy, 60(63.8%) were acid fast bacilli (AFB) positive and 21(22.3%) were identified in the first 
trimester. The mean percentage adherence to anti-retroviral drugs was 95.9% (±5.3). None of the participant 
smoked cigarette. Seventy three {73 (77.7%)} had contact with TB infected or suspected person in the last three 
months. Treatment outcome in mother showed that 74(78.7%) were cured, 8(8.5%) relapsed while 12 (12.8%) 
had treatment failures. Among the babies, 83(88.3%) were born alive. Women with both poor adherence 
(<90%) and with positive TB contact, but neither factor alone, were half-fold less likely to be cured compared 
with women with both good adherence (>95%) and no TB contact (OR=0.59, CI=0.45-0.95 and p=0.014). Cure 
rate was substantially lower in this study. This calls for extra strategies such as routine TB screening in 
antenatal clinics, strict adherence to national guidelines in the treatment of HIV/TB co-infections, focused 
antenatal care and comprehensive Prevention of Mother to Child Transmission (PMTCT) care and treatment. 
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INTRODUCTION 
A steady association between Human 
Immunodeficiency Virus (HIV) and Tuberculosis 
(TB) infections has been widely documented. Over 
nine million new cases of tuberculosis (TB) occur 
annually throughout the world. While most of 
these cases can safely and effectively be treated, 
complications can occur during TB treatment, 
because of anti-TB drug resistance, poor 
adherence, drug-drug interactions, and toxicity 
(Whalen, 2007). Human Immunodeficiency Virus 
(HIV) has contributed to a global resurgence of 
tuberculosis (Corbett et al., 2003). In Sub-Saharan 
Africa, the prevalence of HIV is about 5%-35% of 
the adult population, and one-third to one-half of 
HIV-infected individuals is co-infected with 
Mycobacterium tuberculosis (WHO, 2006). Women     
are special group at risk for contacting these   
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infections. Pregnant infected women are however 
at a greater risk because the physiological state of 
pregnancy could be overwhelming with stress 
which may further compromise an already depleted 
immune status. The two most common 
opportunistic diseases encountered in HIV-related 
lung complications during pregnancy are infection 
with Pneumocystis jiroveci and Mycobacterium 
tuberculosis (Saade, 1997).  
 
The effects of TB on pregnancy depend upon 
various factors such as type, site and extent of the 
disease, stage of pregnancy when management 
gets instituted, nutritional status of mother, 
presence of concomitant disease, immune status 
and co-existence of HIV infection, availability of 
facilities for early diagnosis and treatment 
(McIntyre, 2003;Loto and Awowole, 2011). In a 
South African study, TB was the third leading cause 
of maternal mortality; mostly in combination with 
HIV-infection (Khan et al., 2001). It is also the most 
common cause of deaths in HIV-positive adults 
living in developing countries, despite being a 
preventable and treatable disease (Corbett et al., 
2003). Fifty four per cent maternal deaths caused 
by tuberculosis were attributable to Human 
Immunosuppressive Virus-1 infection (Khan et al., 
2001). Increased susceptibility to TB complications 
may continue to be a major cause of maternal 
mortality in high prevalence HIV areas (Pillay et al., 
2001; Corbett et al., 2002).  
 
However, some studies have shown that pregnant 
patients with active tuberculosis may only have 
few of the typical symptoms (Carter and Mates, 
1994), thus stressing the need for a high index of 
suspicion by care providers. There is general 
agreement that appropriately treated tuberculosis 
does not worsen the outcome of pregnancy. 
Tuberculosis that developed during pregnancy can 
be successfully treated without harm to the 
developing foetus if diagnosed early enough. If 
anti-tuberculosis treatment (ATT) is started early 
in pregnancy, the outcome would be the same as 
for non-pregnant patients, whereas late diagnosis 
and care is associated with 2-fold increase in 
obstetric morbidity such as pre-maturity and low 
birth weight (WHO, 2002). Besides, the availability 
of appropriate diagnostic/therapeutic facilities 
and/or affordability of their use tend to result in 
poor management and outcome in pregnancy. 
Treatment requires a coordinated 
multidisciplinary approach to ensure that the best 
management is offered and that compliance with 
medication is maintained.  
 
Depending on CD4 count and gestational age at 
initiation of treatment, ART treatment regimen for 
HIV positive pregnant women usually combine 
first line antiretroviral drugs such as Zidovudine, 
Lamivudine, nevirapine or Efavirence or a 
Tenovovir based regimen. Anti-TB drugs include 
isoniazid and rifampicin, pyrazinamide and 
ethambutol based regimen to be given in the 
initiation phase and isoniazid and ethambutol in 
continuation phase of DOTS therapy (FMOH, 
2005). However, since several women in 
developing countries do not have access to prompt 
and complete treatment and even PMTCT. The true 
prevalence of coexisting TB and HIV among 
pregnancy may not be ascertained in many 
countries and may require extensive research, 
though most literature testified to the rarity of the 
presentation. 
 
Nigeria has the fourth highest burden of 
tuberculosis (TB) in the world, with an annual 
incidence of 311 cases per 100,000 population and 
a mortality rate of 81 per 100,000 population in 
2006 (WHO, 2008). Nigeria also have HIV sero-
prevalence rate of 4.4%, the third highest infection 
burden in the world while about 21% of all TB 
patients are dually infected with TB and HIV (Ref). 
With the advent of the Directly Observed Treatment 
Short Course) DOTS initiated by the National 
Tuberculosis and Leprosy Control Program 
(NTBLCP) in 1993 to streamline treatment and 
coordinated efforts at TB surveillance, case 
detection rate in Nigeria was 23% while treatment 
cure rate was as high as 76%. This appreciable cure 
rate of TB cases using DOTs is not only in Nigeria, 
but virtually all countries where the strategy has 
been holistically adopted (WHO, 2006). 
 
Nevertheless, records of TB and HIV co-existing in 
pregnancy are not readily available routinely in 
Nigeria. The paucity of data on this subject could 
attest to rare presentations of TB and HIV co-
infections among pregnant women. Situation is 
worsened by the growing cases of multi drug 
resistant TB in the face of antiretroviral drugs and 
changing prevalence of HIV epidemics. It is thus 
important to examine possible influence of 
pregnancy state on outcomes of DOTS programme 
which as at present exists in virtually all the 774 
local government area councils in Nigeria.  




The objective of this study is to determine 
treatment outcomes among pregnant co-infected TB 
and HIV client in Lagos in South-western Nigeria. 
 
METHODOLOGY 
Study Design and Site 
This is a retrospective, analytical study of treatment 
outcomes among pregnant co-infected HIV-TB 
clients seen in selected general hospitals in Lagos 
state between January, 2008 and December, 2009. 
In Lagos state, most general hospitals have projects 
supported by donor agencies, with standard DOTS 
programmes integrated into HIV treatment and 
control programmes. Donor agencies usually 
provide HIV test kits, ARVs and related logistics. 
The National Tuberculosis and Leprosy Control 
programme under Federal Ministry of Health is the 
major source of supports for DOTs programmes in 
Nigeria.  
Division of facilities or sites into comprehensive or 
stand alone has been the major responsibility of 
Lagos State Action Committee on HIV/AIDs based 
on ability to manage HIV and co-infections in 
pregnancy. Ten out of fourteen general hospitals in 
the state designated as comprehensive sites (with 
resources to manage both HIV and TB co-infection 
treatments) were randomly selected for this study. 
Eligibility criteria include all respondents that were 
pregnant, HIV positive, enrolment into facility 
PMTCT care, and those with no other obstetrics 
diseases or diagnosis. All eligible cases seen within 
the period were reviewed because of perceived rare 
presentation of TB and HIV co-existing in 
pregnancy. Ethical approval was obtained from the 
hospital authority and ethical review committee of 
the state hospital management board. 
 
HIV Testing 
HIV infection was diagnosed among the pregnant 
women using the national serial algorithm HIV 
testing method which employs the use of rapid test 
kits for screening and confirmation (FMOH, 2003). 
Three test kits were in the serial algorithm. 
“Determine” (Abbot Diagnostics) was first used on 
the sample and if non-reactive or negative, further 
testing stops at this stage. If reactive, “UniGold” 
(Trinity Biotech USA) was then used for 
confirmation. Discordant result was resolved with 
“Startpack” (manufactured by Chembio Diagnostics 
Systems) and the outcome of this test kit and 




Tuberculosis were diagnosed either using sputum 
microscopy or clinically with a high index of 
suspicion among clients with persistent cough of 
more than three weeks and other signs and 
symptoms (FMOH, 2005). A clinical diagnosis of TB 
was based on history of persistent cough for a 
period of three weeks or more and not responding 
to conventional antibiotics. Adherence to 
medications was measured by making enquiries 
from clients, through routine monthly pill counts 
and review of pharmacy pick-up records. Though 
adherence of 100% is always the target while 
managing clients, missing drugs  one or twice in a 
month usually attract about 95%, three to four  
attracts 91 to 95, while missing pills 5 or more 
times in a month usually attracts adherence score 
of or less than 90% (NACA, 2005). Case notes of all 
96 newly diagnosed for TB clients seen within the 
study period were reviewed at the PMTCT and 
DOTS clinics, and secondary data such as socio-
demographic characteristics and treatment 
outcomes for TB in the mother were obtained using 
a standard checklist designed to collect data from 
case notes.  
 
Measurement of Treatment Outcomes 
Treatment outcomes were measured at the 
completion of the eight months DOTS regimen 
when clients would have been re-assessed for TB 
diagnosis, either to have been cured, treatment 
failure, relapse or as the case may be. Data was 
analysed using EPI Info software, and frequency 
tables generated. Associations between categorical 
variables were computed at a significant P level less 
than or equal to 0.05. Odds ratios values were 
computed to determine cause-effect associations 
between relevant variables that may contribute to 
occurrences of mortality and morbidity. 
 
RESULTS 
Out of the 96 cases, 94 (97.9%) had complete 
management data evident for a period of about one 
year after commencement of treatment, and their 
case notes were analysed. The remaining two 
unanalysed though diagnosed were lost to follow 
up, with no record of continued medications or 
treatments and no delivery or post - partum 
records in the health facility. Table 1 shows the 
socio-demographic characteristics of respondents. 
Seventy (74.5%) respondents were in the age group  
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25 to 34 years. The mean age was 30.8 (+3.9) years. 
Eighty one (86.2%) respondents were married 
while 8 (8.5%) were single. About 61 (64.9%) had 
secondary education. Table 2 shows that only 16 
(17.1%) were clinically diagnosed for tuberculosis, 
while the rest were identified through sputum 
microscopy. Among those identified through 
microscopy, 60 (63.8%) were AFB positive. Twenty 
one (22.3%) were identified in the first trimester 
while 56 (59.6%) were identified in the second. 
Level of adherence to anti-TB and ARVs 
medications was assessed to be as high as above 
95% among 58 (61.6%) respondents.  
 













Table 2: Treatment Outcomes in TB-HIV  
Co-infected Pregnant Women 
 
Variable Frequency (%) 



















Adherence to Anti TB 
Drug/Anti-retroviral 








Risk Factors for TB (Yes 
option only) 
Respondent smokes cigarette 
Had contact with TB infected 



















The mean percentage adherence was 95.9 (±5.3). 
None of the participants smoked cigarette. Seventy-
three (73) (77.7%) had contact with TB infected or 
suspected person in the last three months. 
Treatment outcome in mother shows that 74 
(78.7%) were cured, 8 (8.5%0 relapsed while 12 
(12.8%) had treatment failure. 83 (88.3%) babies 
were born alive. 
 
Further analysis shows that a significant 
association exists between treatment outcome in 
mothers and age of mother with AFB (N=60, 
X2=94.0, p=0.001), level of adherence with drugs 
(N=58, X2=71.0, p=0.001) and outcome of babies at 
birth (N=41, X2=31.8, p=0.003). Further logistics 
regression analysis showed that women with both 
poor adherence (<90%) and with positive TB 
contact, but neither factor alone, were half fold less 
likely to be cured compared with women with both 
good adherence (>95%) and no TB contact 
(OR=0.59, CI=0.45-0.95, p=0.014) 
 
DISCUSSION 
In this study, few clients were clinically diagnosed 
through persistent cough and or haemoptysis and 
other typical presentations. Among clients 
identified by sputum microscopy, about two thirds 
were positive for AFB. Diagnosis by X-rays may not 
feature among these pregnant clients because of 
potential teratogenicity of X-rays in pregnancy. A 
delay in diagnosis of TB in pregnancy could 
however occur if clinicians continue to wait for a 
history of protracted episode of coughing, instead 
of a high index of suspicion for tuberculosis in 
clients with a history of cough in addition to some 
other clinical signs and symptoms.  
 
Many clinicians would usually confirm their clinical 
diagnosis by sending clients for sputum 
microscopy, since TB screening is not mandatory 
for all women in pregnancy. A possible argument is 
to assess the clinical judgment on a single positive 
sputum microscopy as opposed to three positive 
tests, but this calls for more research regarding its 
validity in correctly diagnosing tuberculosis in 
pregnant women. The cure rate observed in this 
study is low when compared with the WHO target 
of achieving 85% cure rates using DOTs strategy 
(WHO, 2008). Among TB-HIV/TB co-infected non-
pregnant clients in Nigeria, a cure rate of 12.7% 
was reported (Njepuome and Odume, 2009). The 
study further reported that the default rate was 
higher among the clients co-infected with HIV.  
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Another African study also suggested that TB 
patients co-infected with HIV had worse treatment 
outcomes (Rustomjee et al., 2004). Although, no 
death was reported in this present study as 
supported by another study (Jana et al., 1994), high 
maternal mortality has been associated with 
puerperal women with TB and those with HIV co-
infection (Ormerod, 2001; Khan et al., 2001).  Our 
observation may be as a result of the relatively low 
sample size with limitations such as inability to 
include cases of extra-pulmonary TB, inability to 
study drug resistance and treatment outcomes 
among babies. Additionally, the retrospective 
nature of the study made it inconclusive to fully 
ascertain the actual number of women with 
confirmed cases of TB using sputum microscopy as 
standard, and the actual number of non-smokers 
based on extent of documentations. Therefore, 
there is a need to carry out more extensive research 
on the subject. 
 
Adherence in this high-risk group is important to 
improve clinical outcomes as well as prevent Multi-
Drug Resistance (MDR) that could cause relapse 
and high failure rates (Paterson et al., 2000; Abaasa 
et al., 2008, Mellins et al., 2008). In this study, there 
was an association between adherence to anti-
retroviral drugs and anti-TB and outcome of 
treatment in mothers. Treatment outcomes might 
have improved because of a continuing emphasis 
on serial adherence counselling sessions adopted in 
most PMTCT programmes on the use of both ARVs 
and anti-TB drugs, strong political will of 
stakeholders to supply drugs and logistics, as well 
as strong commitment of relevant health care 
workers.   
 
Nevertheless, about one fifth was found to have 
relapsed or had treatment failure. This is 
comparative to figures reported by other Nigerian 
authors (Lawson et al., 2010; Lawson et al., 2011) 
but more importantly suggested that MDR-TB is 
gradually becoming an issue in many countries 
including Nigeria. Local studies have reported a 
prevalence of about 8-13% (Lawson et al., 2010; 
Lawson et al., 2011). Perceptibly, this could pose 
danger to the control of tuberculosis and outcomes 
of treatments among women with TB and HIV co-
infections. It is thus important for health-care 
workers to routinely make enquiries about 
adherence from clients as well as monitor 
adherence indicators such as drug pick-ups and pill 
counts.  
 
In conclusion, HIV infections and tuberculosis co-
existence was recognised among pregnant women 
in some health facilities in South-western Nigeria. 
With routine TB screening in antenatal clinics and 
proper management of cases, a high cure rate is 
feasible. Sustained strategies against TB- HIV co-
infection cannot be over-emphasised. Such 
strategies include routine TB screening in antenatal 
clinics, a high index of suspicion for TB among HIV 
positive pregnant women and proper management 
of cases according to the national guidelines. 
Appreciable collaboration and advocate for strong 
political will for HIV and TB control programmes to 
sustain cure rates should thus be sustained. 
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